A new NIH-funded project will study why C. diff and some E. coli become harmful. Learn about its methods, limitations and practical meaning.
On October 15, 2026, WashU Medicine announced that researchers at Washington University School of Medicine in St. Louis and Northwestern University Feinberg School of Medicine had received nearly $11 million to investigate why some gut bacteria become harmful. The grant comes from the National Institute of Allergy and Infectious Diseases, part of NIH, and supports research on Clostridioides difficile and a type of Escherichia coli.
The project builds on an existing biological distinction: a person can carry a potentially harmful organism without having the illness associated with it. Colonization means an organism is present. Disease involves more than its presence alone.
WashU’s announcement illustrates this distinction through Clostridioides difficile, often called C. diff. Some people carry it without symptoms. In others, the bacterium produces substances called toxins that damage tissue.
The Escherichia coli pathway presents a different problem. WashU describes particular gut-resident E. coli strains reaching the bladder and causing a urinary tract infection, or UTI. Here, the question includes where the bacteria are found rather than only whether they are present.
The established background also includes the protective role of the microbiome, the community of microbes living in the body. CDC explains that antibiotics can affect helpful members of that community. When the microbiome is disrupted, harmful germs can sometimes grow more easily. CDC also notes an association between antibiotic use and C. diff infection.
These points make a simple division into “good” and “bad” bacteria incomplete. The new collaboration starts from that complexity rather than overturning it. Thinking about the gut as a microbial community provides a more useful foundation than treating every organism’s name as a verdict on health.
What stands out in WashU’s announcement is the plan to examine bacterial behavior alongside the surrounding gut ecosystem. The researchers will study microbial genes, chemical signals and viruses. Their central question is what separates quiet carriage from disease in people who harbor these organisms.
Gautam Dantas of WashU Medicine leads the collaboration. Erik R. Dubberke co-leads the C. difficile arm, while Northwestern’s Jennie H. Kwon co-leads the E. coli arm.
According to WashU, the researchers plan to draw on a repository of more than 30,000 stool samples collected over 15 years. The samples will be grouped by infection and toxin status rather than treated as one undifferentiated collection.
The announced groups include:
This design puts an important distinction at the center of the investigation. Finding C. diff is one observation. Finding illness alongside toxin production is another. Comparing these groups gives the team a way to investigate what differs between those situations.
WashU says genetic sequencing will be used to look for potentially protective microbes. Chemical analyses will examine signals associated with toxin production or its restraint. Together, these approaches ask both who is present and what conditions accompany harmful activity.
That distinction matters when interpreting a future finding. A result about a bacterium’s presence would answer a different question from a result about toxin activity. The project’s design recognizes that difference from the beginning.
The team also plans viral profiling to assess whether viruses that infect C. diff may affect toxin activity. Viruses that target bacteria are called bacteriophages, or phages.
This part of the work extends the investigation beyond a bacteria-only view of the gut. The researchers are asking whether interactions involving viruses belong in the explanation for different patterns of C. diff behavior. Readers unfamiliar with these organisms can find background on the gut’s nonbacterial residents.
The chemical and viral analyses address related but distinct questions. One examines signals associated with toxin production or restraint. The other examines viruses that infect the bacterium. Both sit alongside the search for microbial partners that may be protective.
For the recurrent-UTI arm, WashU says researchers plan to analyze stool and urine collected over a six-month period. The patients are described as mostly women.
The team will compare UTI-causing E. coli found only in the gut with strains found in the bladder of the same person. It will examine bacterial and viral genes as well as chemical signals.
This comparison brings the location of the bacteria into focus. The study is not simply asking whether a person carries a strain associated with UTIs. It is asking what distinguishes bacteria remaining in the gut from those found in the bladder.
The two research arms therefore address different routes to harm. The C. diff work centers on toxin-associated illness. The E. coli work follows a pathway from gut residence to bladder infection. Studying them within one collaboration does not make them the same biological problem.
Dantas describes an ambition to use knowledge of these factors to help assess patient risk earlier. According to WashU, the findings could inform future risk-screening tools or AI-powered diagnostics.
The project also includes the possibility of targeted approaches that do not rely on antibiotics. Dantas points to microbial partners or chemical signals that keep C. diff quiet as possible leads for future work, including approaches involving probiotics.
The logic is more specific than adding a broadly described “helpful” bacterium. The researchers want to identify the particular partners and conditions associated with restraint of harmful behavior. That is the research question behind the proposed treatment direction.
The central limitation is the stage of the work: this is a grant announcement, not a report of completed study results. It describes planned analyses and intended outcomes. It does not report that the team has identified the triggers behind either disease pathway.
The size of the stool repository also needs careful interpretation. A count of samples is not a count of individual patients. WashU does not provide group-level sample counts, the number of patients in the recurrent-UTI arm or the grant’s duration.
The human-sample comparisons will look for patterns associated with carriage and disease. Those patterns alone would not establish that a particular microbe or chemical signal causes the difference. WashU says mouse models will help investigate patterns identified in the C. diff samples. Findings in those models would still require appropriate human validation.
The UTI arm’s population also shapes the scope of future conclusions. Because participants are described as mostly women with recurrent UTIs, its eventual findings will need to be interpreted in that context rather than automatically applied to every adult.
Finally, the proposed diagnostics and targeted treatments are research goals. The announcement does not establish a personal risk test, a dietary intervention or a probiotic approach for preventing these infections. The reference to probiotics is an investigator’s proposed direction, not evidence that an available supplement reproduces the hoped-for effect.
For everyday eating, the realistic takeaway is to avoid turning this announcement into another reason for unnecessary restriction. Its value lies in the questions it asks about bacterial behavior, not in a new list of foods to eat or avoid.
The same distinction matters when considering gut supplements. A proposal to investigate protective microbial partners is different from evidence supporting a particular product. Reading the proposed mechanism carefully helps keep that boundary clear.
CDC advises using antibiotics only when needed. Questions about prescribed treatment or recurring symptoms belong with a qualified healthcare professional who can assess individual circumstances, rather than prompting a self-directed change based on this headline.
The research may eventually help clinicians distinguish quiet carriage from greater risk. For now, it offers a more precise way to think about gut residents: their presence matters, but so do their behavior and surroundings.
Daily food decisions remain with the adult making them, while DigestGenius supplies educational context for the microbiome headlines that may influence those choices. Its freely available articles and detailed resources connect digestion with nutrition, helping readers separate promising research on resident bacteria from established evidence without presenting a single dietary approach as suitable for everyone.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.
Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog
